Genotype-Guided vs. Conventional Oral P2Y12 Inhibitors in Acute Coronary Syndrome: A Combined Analysis of TAILOR-PCI and POPular Genetics (JACC Cardiovascular Interventions February 2026)-Article: Genotype-Guided vs. Conventional Oral P2Y12 Inhibitors in Acute Coronary Syndrome: A Combined Analysis of TAILOR-PCI and POPular Genetics

Article: Genotype-Guided vs. Conventional Oral P2Y12 Inhibitors in Acute Coronary Syndrome: A Combined Analysis of TAILOR-PCI and POPular Genetics

Back to course

Pdf Summary

This individual participant data meta-analysis combined results from two randomized controlled trials (TAILOR-PCI and POPular Genetics), involving 6,734 acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI), to evaluate the efficacy and safety of genotype-guided oral P2Y12 inhibitor therapy compared with conventional treatment.<br /><br />Background: CYP2C19 loss-of-function (LoF) genetic variants impair clopidogrel metabolism, reducing its effectiveness and increasing thrombotic risk. Genotype-guided therapy individualizes antiplatelet treatment by selecting potent inhibitors (prasugrel/ticagrelor) for LoF allele carriers and clopidogrel for noncarriers to balance ischemic and bleeding risks.<br /><br />Key Findings: <br />- Overall, genotype-guided therapy did not significantly alter the primary safety endpoint (Bleeding Academic Research Consortium [BARC] type 2, 3, or 5 bleeding) or the primary efficacy endpoint (major adverse cardiovascular events [MACE]) at 12 months compared to conventional therapy.<br />- However, genotype guidance reduced myocardial infarction incidence (adjusted hazard ratio [HR] 0.68) and net adverse cardiovascular events (NACE; composite of MACE and bleeding) (HR 0.85).<br />- When analyzed by strategy, genotype-guided de-escalation (switching noncarriers from potent inhibitors to clopidogrel) significantly reduced bleeding (HR 0.77) and NACE (HR 0.77) without increasing MACE risk.<br />- Genotype-guided escalation (switching carriers from clopidogrel to potent inhibitors) showed no significant differences in safety or efficacy endpoints; however, it was associated with a non-significant trend toward reduced myocardial infarction and increased bleeding.<br />- The benefits of genotype-guided therapy, especially de-escalation, were most pronounced within the first 90 days post-PCI, a critical period for balancing bleeding and thrombotic risks.<br /><br />Clinical Implications: These results support integrating CYP2C19 genetic testing in ACS patients undergoing PCI to guide P2Y12 inhibitor selection, particularly favoring genotype-guided de-escalation strategies to minimize bleeding without compromising efficacy. Early implementation post-PCI is crucial due to the time-dependent benefit observed.<br /><br />Limitations: The study excluded patients with chronic coronary syndromes or oral anticoagulant use to ensure homogeneity. The statistical power to detect differences in escalation strategy outcomes was limited, and broader guideline endorsements remain cautious pending more extensive data.<br /><br />Conclusion: In ACS patients undergoing PCI, genotype-guided P2Y12 inhibitor therapy, notably de-escalation based on CYP2C19 genotype, improves net clinical outcomes by reducing bleeding and composite adverse events without raising ischemic complications, primarily benefitting patients in the early months post-intervention.

Keywords

acute coronary syndrome

percutaneous coronary intervention

P2Y12 inhibitor

CYP2C19 genotype

genotype-guided therapy

clopidogrel metabolism

prasugrel

ticagrelor

bleeding risk

major adverse cardiovascular events